Pluristem Therapeutics Share Price Nasdaq
Equities
Biotechnology & Medical Research
Sales 2022 | 234K 18.45M | Sales 2023 | 287K 22.63M | Capitalization | 32.98M 2.6B |
---|---|---|---|---|---|
Net income 2022 | -41M -3.23B | Net income 2023 | -28M -2.21B | EV / Sales 2022 | 58 x |
Net cash position 2022 | 26.21M 2.07B | Net cash position 2023 | 10.27M 809M | EV / Sales 2023 | 79.1 x |
P/E ratio 2022 |
-0.96
x | P/E ratio 2023 |
-1.04
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 76.12% |
Managers | Title | Age | Since |
---|---|---|---|
Yaky Yanay
CEO | Chief Executive Officer | 52 | 31/10/06 |
Director of Finance/CFO | 40 | 30/04/13 | |
Zami Aberman
CHM | Chairman | 70 | 25/09/05 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 73 | 14/07/21 | |
Lorne Abony
BRD | Director/Board Member | 55 | 10/07/23 |
Zami Aberman
CHM | Chairman | 70 | 25/09/05 |
1st Jan change | Capi. | |
---|---|---|
+29.77% | 49.46B | |
+1.00% | 42.58B | |
+50.47% | 42.49B | |
-5.26% | 29.09B | |
+13.68% | 26.61B | |
-22.99% | 18.64B | |
+8.22% | 13.16B | |
+32.41% | 12.55B | |
-1.62% | 11.98B |